AGMB revenueFY2025€1.61M
- FY YoY
- +32.1%
AGMB revenue was €1.61M for fiscal 2025 (ended Dec 31, 2025), up 32.1% from fiscal 2024.
AgomAb Therapeutics NV (AGMB) financials
For fiscal 2025 (ended Dec 31, 2025), AgomAb Therapeutics NV reported €1.61M of revenue and -€62.55M of net income. Figures are in EUR, the currency of its SEC filings.
- Revenue, FY2025
- €1.61M
- Revenue growth, YoY
- +32.1%
- Net income, FY2025
- -€62.55M
- Net margin
- -3887.3%
- EPS, diluted, FY2025
- -€143.22
- Cash
- €86.42M
FY2023FY2025
FY2023FY2025
AGMB revenue and earnings growth
AGMB net incomeFY2025-€62.55M
AGMB net income was -€62.55M for fiscal 2025 (ended Dec 31, 2025), compared with -€46.27M in fiscal 2024.
AGMB EPSFY2025-€143.22
AGMB diluted EPS was -€143.22 for fiscal 2025 (ended Dec 31, 2025), compared with -€107.09 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | €1.61M | €1.22M | €245.0K |
| Research and development | €48.88M | €39.31M | €26.31M |
| Selling, general and admin | €12.79M | €10.13M | €6.10M |
| Operating income | -€59.27M | -€48.02M | -€31.19M |
| Interest expense | €60.0K | €67.0K | €31.0K |
| Pre-tax income | -€62.55M | -€46.26M | -€12.01M |
| Income tax | - | €4.0K | -€619.0K |
| Net income | -€62.55M | -€46.27M | -€11.39M |
| EPS, basic | -€143.22 | -€107.09 | -€35.63 |
| EPS, diluted | -€143.22 | -€107.09 | -€35.63 |
| Diluted shares | 541,126 | 541,126 | 541,126 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | €86.42M | €171.46M | €122.40M |
| Current assets | €121.24M | €173.84M | - |
| Goodwill | €8.61M | €8.61M | - |
| Total assets | €153.71M | €206.36M | - |
| Current liabilities | €18.59M | €9.13M | - |
| Total liabilities | €22.80M | €18.28M | - |
| Shareholders' equity | €130.90M | €188.08M | €151.44M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -€51.74M | -€46.83M | -€24.59M |
| Investing cash flow | -€33.00M | -€675.0K | €40.00M |
| Financing cash flow | -€338.0K | €96.76M | €79.32M |
| Stock-based compensation | €5.36M | €1.07M | €2.16M |
| Depreciation and amortization | €219.0K | €311.0K | €99.0K |
Key ratios
Source: XBRL data AgomAb Therapeutics NV files with the SEC, latest filing dated Apr 23, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
AGMB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AGMB | €1.61M | +32.1% | -€62.55M | -3887.3% | $371.6M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
AGMB FAQ
7 questionsWhat is AGMB revenue?
AgomAb Therapeutics NV (AGMB) reported €1.61M of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 32.1% from the year before.Is AGMB profitable?
No. AgomAb Therapeutics NV reported a net loss of €62.55M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does AGMB have?
AgomAb Therapeutics NV reported €86.42M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is AGMB revenue growing?
AgomAb Therapeutics NV's revenue changed +32.1% in fiscal 2025, to €1.61M.What is AGMB earnings per share?
Diluted earnings per share were -€143.22 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did AGMB last report financial results?
The latest statements here come from AgomAb Therapeutics NV's 20-F filed on Apr 23, 2026, covering the period ended Dec 31, 2025.Where does this AGMB financial data come from?
Quantisnow builds these statements from the structured XBRL data AgomAb Therapeutics NV files with the SEC. It is provided for information only and is not investment advice.